Literature DB >> 28533211

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

Jörg T Regula, Peter Lundh von Leithner, Richard Foxton, Veluchamy A Barathi, Chui Ming Gemmy Cheung, Sai Bo Bo Tun, Yeo Sia Wey, Daiju Iwata, Miroslav Dostalek, Jörg Moelleken, Kay G Stubenrauch, Everson Nogoceke, Gabriella Widmer, Pamela Strassburger, Michael J Koss, Christian Klein, David T Shima, Guido Hartmann.   

Abstract

Entities:  

Year:  2017        PMID： 28533211      PMCID： PMC5494529          DOI： 10.15252/emmm.201707895

Source DB:  PubMed          Journal:  EMBO Mol Med        ISSN： 1757-4676            Impact factor:   12.137


× No keyword cloud information.
  2 in total

1.  Anti-VEGF-A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study.

Authors:  Anne Wolf; Thomas Langmann
Journal:  EMBO Mol Med       Date:  2019-05       Impact factor: 12.137

2.  Variable heavy-variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly.

Authors:  Joerg Thomas Regula; Sabine Imhof-Jung; Michael Mølhøj; Joerg Benz; Andreas Ehler; Alexander Bujotzek; Wolfgang Schaefer; Christian Klein
Journal:  Protein Eng Des Sel       Date:  2018-07-01       Impact factor: 1.650
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.